<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5177">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04788433</url>
  </required_header>
  <id_info>
    <org_study_id>ROCCO-197/2020</org_study_id>
    <nct_id>NCT04788433</nct_id>
  </id_info>
  <brief_title>Registry of Coronavirus Complications - CORRELATION WITH GLYCOMIC PROFILE</brief_title>
  <acronym>ROCCO</acronym>
  <official_title>ROCCO - Registry of Coronavirus Complications. Prospective Observational Study on Coronavirus Complications and Correlation With Glycomic Profile</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Papa Giovanni XXIII Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GENOS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Papa Giovanni XXIII Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      COVID infection has resulted in multi-organ injury and may result in cardiovascular,&#xD;
      pulmonary, neurological, and muscular damage. It is associated with significant asthenia and&#xD;
      the long-term effects of the infection are still unclear, particularly for the development of&#xD;
      pain and delayed functional rehabilitation.&#xD;
&#xD;
      Glycomics &quot;is the systematic study of the structure of glycans in a given cell type or&#xD;
      organism. Glycans are complex oligosaccharides attached to proteins and lipids that regulate&#xD;
      a variety of organic processes, including immunity Thus, glycans may influence different&#xD;
      moments of the response to the virus and involved in the clinical severity of the disease,&#xD;
      but may also change depending on the severity of symptoms and the organic response to&#xD;
      SARS-CoV-2 infection.&#xD;
&#xD;
      Glycomic data could provide important insights into interindividual differences at the&#xD;
      molecular level that directly interact with SARS-CoV-2 and the development of mid- and&#xD;
      long-term side effects. The ability to identify early those susceptible to developing&#xD;
      COVID-19 infection and at higher risk for COVID-19 with unfavorable outcomes long after&#xD;
      infection would help guide therapeutic strategy and provide important guidance for rational&#xD;
      health care organization, which is of outmost importance.&#xD;
&#xD;
      Long-term outcome data regarding post-COVID patient functional capacity and glycomics will be&#xD;
      compared to assess whether there may be differences in protein glycosylation that may predict&#xD;
      patient outcome.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 4, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Glycomic profile as predictor of long-term morbidity</measure>
    <time_frame>1 year</time_frame>
    <description>Analysis of total plasmatic and IgG glycans composition; analysis of IgG glycopeptides. Correlation with pain, severity of the disease and long-term functional rehabilitation</description>
  </primary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">615</enrollment>
  <condition>Chronic Pain</condition>
  <condition>Morbidity, Multiple</condition>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>ROCCO-A (A-symptomatic)</arm_group_label>
    <description>Patients with documented COVID-19 infection and NO symptoms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ROCCO-P (Pauci-symptomatic)</arm_group_label>
    <description>Patients with documented COVID-19 infection and mild symptoms but NO oxygen support)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ROCCO-L (mild)</arm_group_label>
    <description>Patients with documented COVID-19 infection and mild severity - requiring OXIGEN SUPPORT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ROCCO-M (moderate)</arm_group_label>
    <description>Patients with documented COVID-19 infection and moderate severity - requiring OXIGEN SUPPORT by NON-INVASIVE modalities</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ROCCO-S(severe)</arm_group_label>
    <description>Patients with documented COVID-19 infection and severe disease requiring INVASIVE VENTILATION OR EXTRACORPOREAL MEMBRANE OXYGENATION</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>glycomic analysis</intervention_name>
    <description>Analysis of glycans on plasma samples</description>
    <arm_group_label>ROCCO-A (A-symptomatic)</arm_group_label>
    <arm_group_label>ROCCO-L (mild)</arm_group_label>
    <arm_group_label>ROCCO-M (moderate)</arm_group_label>
    <arm_group_label>ROCCO-P (Pauci-symptomatic)</arm_group_label>
    <arm_group_label>ROCCO-S(severe)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Phone interview</intervention_name>
    <description>patients are followed up by phone up to 1 year</description>
    <arm_group_label>ROCCO-A (A-symptomatic)</arm_group_label>
    <arm_group_label>ROCCO-L (mild)</arm_group_label>
    <arm_group_label>ROCCO-M (moderate)</arm_group_label>
    <arm_group_label>ROCCO-P (Pauci-symptomatic)</arm_group_label>
    <arm_group_label>ROCCO-S(severe)</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with documented infection by Sars-CoV2 with different degrees of clinical&#xD;
        severity.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed diagnosis of COVID19 virus infection (buffer/BAL/positive IgG serology)&#xD;
&#xD;
          -  Age &gt;18 years&#xD;
&#xD;
          -  Able to express informed consent to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients unable to express consent,&#xD;
&#xD;
          -  patients aged &lt;18 yr,&#xD;
&#xD;
          -  with signs and symptoms compatible with Covid-19 but without certified diagnosis by&#xD;
             swab/BAL or serological examination of presence of COVID IgG antibodies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dario Bugada</last_name>
    <phone>+393405230454</phone>
    <email>dariobugada@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aast Papa Giovanni Xxiii</name>
      <address>
        <city>Bergamo</city>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DARIO BUGADA, MD</last_name>
      <phone>00390352675113</phone>
      <email>dariobugada@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 7, 2021</study_first_submitted>
  <study_first_submitted_qc>March 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2021</study_first_posted>
  <last_update_submitted>March 7, 2021</last_update_submitted>
  <last_update_submitted_qc>March 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Papa Giovanni XXIII Hospital</investigator_affiliation>
    <investigator_full_name>Dario Bugada</investigator_full_name>
    <investigator_title>Anesthesiologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

